Thermal Extraction Devices

Loading search index…

    Thermal engineering & extraction device archive

    Cannabidiolic Acid (CBDA)

    Identity

    Property Value
    Preferred name Cannabidiolic acid (CBDA)
    IUPAC name 2,4-dihydroxy-3-[(1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-6-pentylbenzoic acid
    CAS number 1244-58-2
    PubChem CID 160570
    Molecular formula C22H30O4
    Molecular mass 358.47 g/mol
    Compound class Phytocannabinoid; dihydroxybenzoic acid (olivetolic acid derivative)
    Stereochemistry Two stereocenters; natural material is (−)-CBDA with (1R,6R) geometry [^1]
    Major synonyms Cannabidiolic acid, CBDA; decarboxylation product is CBD

    Identity notes

    • Some databases list “cannabidiol acid” ambiguously; verify CAS 1244-58-2 / CID 160570 [^1].
    • GC methods without derivatization convert CBDA to CBD in the injector; LC methods are required to measure the acid form directly [^2].

    Physical properties

    Property Value Conditions / Notes
    Boiling point No compound-specific atmospheric boiling point was located. The often-repeated ≈120 °C figure is a study-specific acid-conversion temperature, not a thermodynamic boiling point [^2]
    Melting point Not sharply defined; decomposes on heating (decarboxylation overlaps melting) [^2]
    Decarboxylation To CBD; temperature-, time-, atmosphere-, solvent-, and matrix-dependent. In a vacuum-oven kinetic study, CBDA conversion was measured at 110 °C, with material loss and side chemistry; no universal onset or completion temperature is assigned [^2]
    Oxidation / light sensitivity CBDA oxidation and light-stability behavior are condition-dependent; no compound-specific stability threshold is assigned. CBDA is the primary acidic cannabinoid in fresh hemp flower [^2]
    Known degradation products CBD (decarboxylation) [^2]; secondary oxidative products remain analogies to CBD and are not directly characterized for CBDA

    Boiling point is not a device setpoint. CBDA thermal conversion is condition-dependent and the available evidence does not establish an intact atmospheric boiling point. Vaporizer-chart figures are device or matrix-evaporation temperatures, not thermodynamic boiling points [^2].

    Thermal-extraction context

    In fresh flower, CBDA is the dominant CBD-series analyte; heating can decarboxylate CBDA to CBD, which may then volatilize via vapor-pressure-driven evaporation from the matrix. The thermodynamic boiling point of the pure compound is not a device setpoint or a sample temperature; device setpoint, sample temperature, matrix, and residence time must be reported separately [^2].

    Cannabis occurrence

    • Measured hemp flower batches (CBD-dominant chemotypes) have reported 100–200 mg/g (10–20% w/w) of CBDA plus CBD, with the acid form dominant in fresh material [^3].
    • Measured drug-type flower batches have reported <1% CBDA plus CBD [^3].
    • Values are batch- and report-attached; they are not universal cultivar claims.

    Biosynthesis and processing

    CBDA is biosynthesized from CBGA by CBDAS (CBDA synthase) and competes with THCAS for the shared CBGA pool; the CBDAS/THCAS allele balance determines the CBDA:THCA ratio and chemotype classification (Type I/II/III) [^2]. Drying, curing, and heating progressively convert CBDA to CBD [^2].

    Reported biological activity

    Human evidence

    No verified controlled human study of isolated CBDA was identified for this archive [^4].

    Preclinical animal and in vitro evidence

    Preclinical reports describe anxiolytic-like and antinociceptive-like activity in mice and in vitro anti-inflammatory signaling effects; these do not establish effects in people or at cannabis-relevant inhaled doses 1.

    Industry claims

    Marketed anti-inflammatory/nausea claims for CBDA remain unsupported by controlled human evidence 1.

    Degradation products

    • Primary: CBD (decarboxylation) 2
    • Secondary (oxidative/photolytic): unresolved; CBE-type and quinone products are analogies to CBD, not verified CBDA products

    Sources

    1. Formato M, Crescente G, Scognamiglio M, et al. (−)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research. Molecules. 2020;25(11):2638. doi:10.3390/molecules25112638. PMID 32517131. (Review: anxiolytic-like and antinociceptive-like activity in mouse models; in vitro anti-inflammatory signaling; no controlled human trials of isolated CBDA identified.) Takeda S, Misawa K, Yamamoto I, Watanabe K. Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis. Drug Metab Dispos. 2008;36(9):1917–1921. doi:10.1124/dmd.108.020909. PMID 18556441. (COX-2 inhibition, in vitro.) ↩ ↩2

    2. García-Valverde MT, Sánchez-Carnerero Callado C, Díaz-Liñán MC, et al. Effect of temperature in the degradation of cannabinoids: from a brief residence in the gas chromatography inlet port to a longer period in thermal treatments. Front Chem. 2022;10:1038729. doi:10.3389/fchem.2022.1038729. (GC-injector decarboxylation of acidic cannabinoids; LC methods required for direct acid quantification; degradation products.) Wang M, Wang YH, Avula B, et al. Decarboxylation study of acidic cannabinoids: a novel approach using ultra-high-performance supercritical fluid chromatography/photodiode array-mass spectrometry. Cannabis Cannabinoid Res. 2016;1(1):262–271. doi:10.1089/can.2016.0020. PMID 28861498. (Decarboxylation of acidic cannabinoids at ≈105–120 °C over tens of minutes.) Eyal AM, Berneman Zeitouni D, Tal D, Schlesinger D, Davidson EM, Raz N. Vapor pressure, vaping, and corrections to misconceptions related to medical cannabis’ active pharmaceutical ingredients’ physical properties and co ↩

    Derived navigation generated from structured relationships. Links are labeled by edge class and evidence trace; derived links are navigation, not primary assertions.

    Laboratory reports measuring this compound (1)

    Products with measurements (1)

    Related (4)